相关实验视频

Updated: May 21, 2025

Minimally Invasive Treatment for Thoracolumbar Burst Fracture Using Sagittal Alignment Screws and A Trauma Reduction Device

Minimally Invasive Treatment for Thoracolumbar Burst Fracture Using Sagittal Alignment Screws and A Trauma Reduction Device

Published on: November 8, 2024

在患有类风湿性关节炎的患者中使用infliximab和椎脊椎形

Anna Baukje Lebouille-Veldman^1,2, Tom W J Huizinga³, Rania A Mekary^2,4

¹Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands abveld@gmail.com.

|March 18, 2025

概括

长时间使用infliximab可以预防类风湿性关节炎和椎脊椎形. 这项研究发现,在10年内延长因弗利克西马布治疗后,椎问题风险降低.

科学领域:

类风湿病学类风湿病学
整形外科整形外科整形外科
免疫学免疫学免疫学

背景情况:

类风湿性关节炎 (RA) 可以影响椎脊柱,导致形.
与RA相关的宫脊椎问题的手术减少了.
在RA中预防椎脊柱损伤的Infliximab的作用尚不清楚.

研究的目的:

为了调查infliximab使用时间和RA患者的椎脊椎形之间的关联.
为了确定infliximab是否在10年内对椎提供保护作用.

主要方法:

一项病例控制研究分析了BeSt试验的数据,并对其进行了10年的随访.
侧面X射线评估了亚轴突 (AAS) 和亚轴突 (SAS).
对关键的人口和疾病变量进行调整的后勤回归模型.

主要成果:

宫变形 (AAS/SAS>2mm) 在40%的患者中存在.
每增加一年的INFLIXIMAB使用与11%的椎脊椎形的几率降低有关 (OR:0.89).
调解分析没有显示疾病活性评分 (DAS44) 影响了相关性.

结论:

延长使用infliximab表明,在RA患者中,与椎脊椎变形减少有有益的关联.
这些发现表明,因弗利西马布可能会保护椎脊柱,类似于它对其他关节的影响.
在持续治疗决策中,平衡因弗利西马布的益处与潜在的不良事件至关重要.

关键词:

生物疗法生物疗法这就是Infliximab.类风湿性关节炎类风湿性关节炎类风湿性关节炎

更多相关视频

Anterior Cervical Discectomy and Fusion in the Ovine Model

Anterior Cervical Discectomy and Fusion in the Ovine Model

Published on: October 5, 2009

Cone Beam Intraoperative Computed Tomography-based Image Guidance for Minimally Invasive Transforaminal Interbody Fusion

Cone Beam Intraoperative Computed Tomography-based Image Guidance for Minimally Invasive Transforaminal Interbody Fusion

Published on: August 6, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...